Standard breast cancer classification may overlook important differences
Breast cancer is often classified as either estrogen receptor-positive (hormone-sensitive) or not. However, a new study from Karolinska Institutet suggests that this simplified classification may overlook important biological differences between patients that could affect treatment decisions. The results are published in The Lancet Regional Health – Europe.
Breast cancer is typically classified as either estrogen receptor-positive or estrogen receptor-negative. However, a new study from Sweden suggests this simplified classification may miss important biological differences between patients, potentially impacting treatment decisions. The study, published in The Lancet Regional Health – Europe, found that tumors expressing estrogen receptors could be further categorized on a spectrum, with varying levels of receptor positivity affecting survival rates.
Tumors with low to moderate levels of estrogen receptor expression had worse outcomes compared to those with higher levels. Patients with mild to moderate levels of estrogen receptors may benefit from a combination of chemotherapy and hormone therapy, indicating that the exact level of receptor expression could be crucial in determining treatment.
The researchers stress that their findings come from an observational study and that further research is needed to apply these results in clinical practice.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
